These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32426479)

  • 1. RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
    Eshraghi M; Ramírez-Jarquín UN; Shahani N; Nuzzo T; De Rosa A; Swarnkar S; Galli N; Rivera O; Tsaprailis G; Scharager-Tapia C; Crynen G; Li Q; Thiolat ML; Bezard E; Usiello A; Subramaniam S
    Sci Adv; 2020 May; 6(18):eaaz7001. PubMed ID: 32426479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
    Ahmed MR; Jayakumar M; Ahmed MS; Zamaleeva AI; Tao J; Li EH; Job JK; Pittenger C; Ohtsu H; Rajadas J
    Neurobiol Aging; 2019 Sep; 81():177-189. PubMed ID: 31306812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Alcacer C; Santini E; Valjent E; Gaven F; Girault JA; Hervé D
    J Neurosci; 2012 Apr; 32(17):5900-10. PubMed ID: 22539851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
    Martín-Flores N; Fernández-Santiago R; Antonelli F; Cerquera C; Moreno V; Martí MJ; Ezquerra M; Malagelada C
    Mol Neurobiol; 2019 Mar; 56(3):2092-2100. PubMed ID: 29992529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a combination treatment of KD5040 and
    Ahn S; Song TJ; Park SU; Jeon S; Kim J; Oh JY; Jang J; Hong S; Song MA; Shin HS; Jung YR; Park HJ
    BMC Complement Altern Med; 2017 Apr; 17(1):220. PubMed ID: 28424060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
    BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
    Park HY; Kang YM; Kang Y; Park TS; Ryu YK; Hwang JH; Kim YH; Chung BH; Nam KH; Kim MR; Lee CH; Han PL; Kim KS
    J Neurosci; 2014 Aug; 34(35):11744-53. PubMed ID: 25164669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
    Solís O; Espadas I; Del-Bel EA; Moratalla R
    Neurobiol Dis; 2015 Jan; 73():49-59. PubMed ID: 25281315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
    Ryu YK; Park HY; Go J; Choi DH; Kim YH; Hwang JH; Noh JR; Lee TG; Lee CH; Kim KS
    Mol Neurobiol; 2018 Jul; 55(7):5715-5726. PubMed ID: 29039022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
    Fasano S; Bezard E; D'Antoni A; Francardo V; Indrigo M; Qin L; Doveró S; Cerovic M; Cenci MA; Brambilla R
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21824-9. PubMed ID: 21115823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
    Chotibut T; Fields V; Salvatore MF
    Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
    Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
    Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.